



November 14, 2016

## **AngioDynamics Announces Secondary Offering of 2,500,000 Shares of Common Stock by Selling Stockholders**

ALBANY, N.Y., Nov. 14, 2016 (GLOBE NEWSWIRE) -- AngioDynamics, Inc. (NASDAQ:ANGO) (the "Company"), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced that certain of its stockholders (the "Selling Stockholders") intend to offer for sale in an underwritten secondary offering 2,500,000 shares of common stock pursuant to the Company's shelf registration statement filed with the Securities and Exchange Commission (the "SEC"), of which the Company intends to repurchase from the underwriter 500,000 shares of common stock. The Selling Stockholders will receive all of the net proceeds from this offering. No shares are being sold by the Company. Barclays Capital Inc. will act as underwriter for the offering.

A shelf registration statement (including a prospectus) relating to the offering of common stock was filed with the SEC on October 3, 2013 and became effective on October 11, 2013. Before you invest, you should read the prospectus included in that registration statement and the documents incorporated by reference in that registration statement as well as the prospectus supplement related to this offering. You may obtain these documents for free by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov). When available, copies of the prospectus supplement and accompanying prospectus related to the offering may also be obtained by contacting Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, N.Y. 11717, or by telephone at 888-603-5847 or by emailing [barclaysprospectus@broadridge.com](mailto:barclaysprospectus@broadridge.com).

The offering of these securities will be made only by means of a prospectus supplement and the accompanying prospectus.

This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer to buy the securities may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date of the shelf registration statement.

### **About AngioDynamics**

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products.

### **Note on Forward-Looking Statements**

This release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future, including risks and uncertainties relating to the consummation of the proposed offering by the Selling Stockholders and the risks identified, or incorporated by reference, in the prospectus supplement or accompanying prospectus. As a result of the foregoing considerations, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:

AngioDynamics Inc.

Caitlin Stefanik

(518) 795-1418

[cstefanik@angiodynamics.com](mailto:cstefanik@angiodynamics.com)

Investor Relations Contacts:

FTI Consulting

Jim Polson

(312) 553-6730

[Jim.Polson@fticonsulting.com](mailto:Jim.Polson@fticonsulting.com),

Kotaro Yoshida

(212) 850-5690

[Kotaro.Yoshida@fticonsulting.com](mailto:Kotaro.Yoshida@fticonsulting.com)

Media Contact:

FTI Consulting

Kimberly Ha

(212) 850-5612

[kimberly.ha@fticonsulting.com](mailto:kimberly.ha@fticonsulting.com)

 Primary Logo

Source: AngioDynamics

News Provided by Acquire Media